All Amprologix articles
-
NewsStudies shows new class of antibiotic is effective in tackling MRSA
New research has shown a daily dose of epidermicin NI01 – an antibiotic compound developed by University of Plymouth spinout company Amprologix – is as effective at removing Methicillin-resistant Staphylococcus aureus (MRSA) as the current standard of care.